文献速递白血病

高mTORC1活性驱动急性髓系白血病细胞的糖酵解依赖并增加其对G6PD抑制的敏感性

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.
PubMed 文献 · Leukemia · 2017-03-10

该研究解析了急性髓系白血病(AML)中mTORC1活性与葡萄糖代谢的相互作用。AML细胞中持续过度激活的mTORC1信号促进糖酵解并导致葡萄糖依赖;高mTORC1活性使AML细胞对糖酵解抑制敏感,而关闭mTORC1活性则通过增加线粒体氧化磷酸化实现不依赖葡萄糖的细胞存活。磷酸戊糖途径(PPP)是高mTORC1活性AML细胞糖代谢的重要促存活通路,G6PD过表达与不良预后相关;G6PD抑制剂6-氨基烟酰胺在体外和体内对AML细胞有细胞毒性,并协同增强白血病细胞对化疗的敏感性。

要点

  • AML细胞中mTORC1信号持续过度激活,促进糖酵解并导致葡萄糖依赖。
  • 高mTORC1活性决定AML细胞对糖酵解抑制的敏感性,关闭mTORC1活性则细胞存活转为不依赖葡萄糖。
  • G6PD过表达与AML不良预后相关,G6PD抑制剂6-氨基烟酰胺在体外和体内对AML细胞有细胞毒性并协同增敏化疗。

核心结论

  • 高mTORC1活性造成AML细胞对G6PD抑制的特异性脆弱性,可能成为新的AML治疗策略。

研究设计与样本

  • 研究解析AML细胞中mTORC1活性与葡萄糖代谢的相互作用,并分析癌症基因组图谱AML数据库。

主要发现

  • AML细胞中持续过度激活的mTORC1信号促进糖酵解并导致葡萄糖依赖。
  • 关闭mTORC1活性使AML细胞存活不依赖葡萄糖,并由线粒体氧化磷酸化增加所维持。
  • 磷酸戊糖途径(PPP)是高mTORC1活性AML细胞糖代谢的重要促存活通路。
  • 癌症基因组图谱AML数据库中G6PD过表达与该队列的不良预后相关。
  • G6PD抑制剂6-氨基烟酰胺在体外和体内对AML细胞有细胞毒性,并协同增强白血病细胞对化疗的敏感性。

临床怎么用

  • 作者认为高mTORC1活性造成的对G6PD抑制的特异性脆弱性可能作为新的AML治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alterations in metabolic activities are cancer hallmarks that offer a wide range of new therapeutic opportunities. Here we decipher the interplay between mTORC1 activity and glucose metabolism in acute myeloid leukemia (AML). We show that mTORC1 signaling that is constantly overactivated in AML cells promotes glycolysis and leads to glucose addiction. The level of mTORC1 activity determines the sensitivity of AML cells to glycolysis inhibition as switch-off mTORC1 activity leads to glucose-independent cell survival that is sustained by an increase in mitochondrial oxidative phosphorylation. Metabolic analysis identified the pentose phosphate pathway (PPP) as an important pro-survival pathway for glucose metabolism in AML cells with high mTORC1 activity and provided a clear rational for targeting glucose-6-phosphate dehydrogenase (G6PD) in AML. Indeed, our analysis of the cancer genome atlas AML database pinpointed G6PD as a new biomarker in AML, as its overexpression correlated with an adverse prognosis in this cohort. Targeting the PPP using the G6PD inhibitor 6-aminonicotinamide induces in vitro and in vivo cytotoxicity against AML cells and synergistically sensitizes leukemic cells to chemotherapy. Our results demonstrate that high mTORC1 activity creates a specific vulnerability to G6PD inhibition that may work as a new AML therapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Poulain L, Sujobert P, Zylbersztejn F, et al. High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells. Leukemia. 2017. PMID: 28280275. doi:10.1038/leu.2017.81

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。